Tumour Necrosis Factor-α Gene Polymorphism Is Associated with Metastasis in Patients with Triple Negative Breast Cancer

Scientific Reports

Volumn 5, Issue 1, 2015, Pages

  Li, Hui Hui ^a   Zhu, Hui ^a   Liu, Li Sheng ^a   Huang, Yong ^a   Guo, Jun ^a   Li, Jie ^b   Sun, Xin Ping ^c   Chang, Chun Xiao ^a   Wang, Zhe Hai ^a   Zhai, Kan ^b  

^a SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR;

ADULT; ALLELE; ASIAN CONTINENTAL ANCESTRY GROUP; CAUCASIAN; FACTUAL DATABASE; FEMALE; GENETICS; GENOTYPE; HUMAN; META ANALYSIS; METASTASIS; MIDDLE AGED; ODDS RATIO; REGRESSION ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TRIPLE NEGATIVE BREAST CANCER;

ADULT; ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; DATABASES, FACTUAL; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; REGRESSION ANALYSIS; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85018214298     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/SREP10244     Document Type: Article

References (56)

1. Siegel, R., Ma, J., Zou, Z. & Jemal, A. Cancer statistics, 2014. CA. Cancer J. Clin. 64, 9–29 (2014).
2. Carey, L. A. et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295, 2492–2502 (2006).
3. Blows, F. M. et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med. 7, e1000279 (2010).
4. Goldberg, J. E. & Schwertfeger, K. L. Proinflammatory cytokines in breast cancer: mechanisms of action and potential targets for therapeutics. Curr. Drug Targets 11, 1133–1146 (2010).
5. Allin, K. H., Nordestgaard, B. G., Flyger, H. & Bojesen, S. E. Elevated pre-treatment levels of plasma C-reactive protein are associated with poor prognosis after breast cancer: a cohort study. Breast Cancer Res. 13, R55 (2011).
6. Pierce, B. L. et al. Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J. Clin. Oncol. 27, 3437–3444 (2009).
7. Bazzoni, F. & Beutler, B. The tumor necrosis factor ligand and receptor families. N. Engl. J. Med. 334, 1717–1725 (1996).
8. Leek, R. D. et al. Association of tumour necrosis factor alpha and its receptors with thymidine phosphorylase expression in invasive breast carcinoma. Br. J. Cancer 77, 2246–2251 (1998).
9. Champ, C. E. et al. Weight gain, metabolic syndrome, and breast cancer recurrence: are dietary recommendations supported by the data? Int. J. Breast Cancer 2012, 506868 (2012).
10. Ioculano, M. et al. Tumour necrosis factor mediates E-selectin production and leukocyte accumulation in myocardial ischaemia-reperfusion injury. Pharmacol. Res. 31, 281–288 (1995).
11. Warzocha, K. et al. Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients. J. Clin. Oncol. 15, 499–508 (1997).
12. Nakashima, J. et al. Association between tumor necrosis factor in serum and cachexia in patients with prostate cancer. Clin. Cancer Res. 4, 1743–1748 (1998).
13. Szlosarek, P. W. & Balkwill, F. R. Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. Lancet Oncol. 4, 565–573 (2003).
14. Pileczki, V., Braicu, C., Gherman, C. D. & Berindan-Neagoe, I. TNF-alpha gene knockout in triple negative breast cancer cell line induces apoptosis. Int. J. Mol. Sci. 14, 411–420 (2012).
15. Cariaso, M. & Lennon, G. SNPedia: a wiki supporting personal genome annotation, interpretation and analysis. Nucleic Acids Res. 40, D1308–1312 (2012).
16. Huang, Y. T. et al. Genome-wide analysis of survival in early-stage non-small-cell lung cancer. J. Clin. Oncol. 27, 2660–2667 (2009).
17. Wilson, A. G., di Giovine, F. S. & Duff, G. W. Genetics of tumour necrosis factor-alpha in autoimmune, infectious, and neoplastic diseases. J. Inflamm. 45, 1–12 (1995).
18. Neben, K. et al. Polymorphisms of the tumor necrosis factor-alpha gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma. Blood 100, 2263–2265 (2002).
19. Ho, S. Y. et al. Increased risk of developing hepatocellular carcinoma associated with carriage of the TNF2 allele of the-308 tumor necrosis factor-alpha promoter gene. Cancer Causes Control 15, 657–663 (2004).
20. Kroeger, K. M., Carville, K. S. & Abraham, L. J. The-308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Mol. Immunol. 34, 391–399 (1997).
21. Wilson, A. G. et al. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc. Natl. Acad. Sci. USA 94, 3195–3199 (1997).
22. Yang, Y., Feng, R., Bi, S. & Xu, Y. TNF-alpha polymorphisms and breast cancer. Breast Cancer Res. Treat 129, 513–519 (2011).
23. Chouchane, L., Ahmed, S. B., Baccouche, S. & Remadi, S. Polymorphism in the tumor necrosis factor-alpha promotor region and in the heat shock protein 70 genes associated with malignant tumors. Cancer 80, 1489–1496 (1997).
24. Mestiri, S. et al. Genetic variation in the tumor necrosis factor-alpha promoter region and in the stress protein hsp70-2: susceptibility and prognostic implications in breast carcinoma. Cancer 91, 672–678 (2001).
25. Giordani, L. et al. Association of breast cancer and polymorphisms of interleukin-10 and tumor necrosis factor-alpha genes. Clin. Chem. 49, 1664–1667 (2003).
26. Azmy, I. A. et al. Role of tumour necrosis factor gene polymorphisms (-308 and-238) in breast cancer susceptibility and severity. Breast Cancer Res. 6, R395–400 (2004).
27. Kamali-Sarvestani, E., Merat, A. & Talei, A. R. Polymorphism in the genes of alpha and beta tumor necrosis factors (TNF-alpha and TNF-beta) and gamma interferon (IFN-gamma) among Iranian women with breast cancer. Cancer Lett. 223, 113–119 (2005).
28. Scola, L. et al. Cytokine gene polymorphisms and breast cancer susceptibility. Ann. N. Y. Acad. Sci. 1089, 104–109 (2006).
29. Gaudet, M. M. et al. Genetic variation in tumor necrosis factor and lymphotoxin-alpha (TNF-LTA) and breast cancer risk. Hum. Genet. 121, 483–490 (2007).
30. Gonullu, G. et al. Association of breast cancer and cytokine gene polymorphism in Turkish women. Saudi Med. J. 28, 1728–1733 (2007).
31. Sirotkovic-Skerlev, M. et al. TNF alpha promoter polymorphisms analysis in benign and malignant breast lesions. Exp. Mol. Pathol. 83, 54–58 (2007).
32. Risk, M.-G. C. o. G. S. f. M. H. T. R. B. C. Polymorphisms in the BRCA1 and ABCB1 genes modulate menopausal hormone therapy associated breast cancer risk in postmenopausal women. Breast Cancer Res. Treat 120, 727–736 (2010).
33. Karakus, N. et al. Tumor necrosis factor alpha and beta and interferon gamma gene polymorphisms in Turkish breast cancer patients. DNA Cell Biol. 30, 371–377 (2011).
34. Madeleine, M. M. et al. Genetic variation in proinflammatory cytokines IL6, IL6R, TNF-region, and TNFRSF1A and risk of breast cancer. Breast Cancer Res. Treat 129, 887–899 (2011).
35. Gomez Flores-Ramos, L. et al. Association of the tumor necrosis factor-alpha − 308G > A polymorphism with breast cancer in Mexican women. Genet. Mol. Res. 12, 5680–5693 (2013).
36. Park, K. S. et al. Polymorphisms of tumour necrosis factors A and B in breast cancer. Eur. J. Immunogenet. 29, 7–10 (2002).
37. Kohaar, I. et al. Association of single nucleotide polymorphisms (SNPs) in TNF-LTA locus with breast cancer risk in Indian population. Breast Cancer Res. Treat 114, 347–355 (2009).
38. Pooja, S. et al. Role of ethnic variations in TNF-alpha and TNF-beta polymorphisms and risk of breast cancer in India. Breast Cancer Res. Treat 126, 739–747 (2011).
39. Xu, F. et al. Association of TNF-alpha, TNFRSF1A and TNFRSF1B Gene Polymorphisms with the Risk of Sporadic Breast Cancer in Northeast Chinese Han Women. PLoS One 9, e101138 (2014).
40. Spriggs, D. R., Deutsch, S. & Kufe, D. W. Genomic structure, induction, and production of TNF-alpha. Immunol. Ser. 56, 3–34 (1992).
41. Yu, M. et al. Targeting transmembrane TNF-alpha suppresses breast cancer growth. Cancer Res. 73, 4061–4074 (2013).
42. Chu, W. M. Tumor necrosis factor. Cancer Lett. 328, 222–225 (2013).
43. Wang, J. et al. Tumour necrosis factor alpha-308G/A polymorphism and risk of the four most frequent cancers: a meta-analysis. Int. J. Immunogenet. 38, 311–320 (2011).
44. Smith, K. C., Bateman, A. C., Fussell, H. M. & Howell, W. M. Cytokine gene polymorphisms and breast cancer susceptibility and prognosis. Eur. J. Immunogenet. 31, 167–173 (2004).
45. Skerrett, D. L., Moore, E. M., Bernstein, D. S. & Vahdat, L. Cytokine genotype polymorphisms in breast carcinoma: associations of TGF-beta1 with relapse. Cancer Invest. 23, 208–214 (2005).
46. Gallicchio, L. et al. Body mass, polymorphisms in obesity-related genes, and the risk of developing breast cancer among women with benign breast disease. Cancer Detect. Prev. 31, 95–101 (2007).
47. Erdei, E. et al. Polymorphisms in cytokine genes and serum cytokine levels among New Mexican women with and without breast cancer. Cytokine 51, 18–24 (2010).
48. Bauer, K. R. et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 109, 1721–1728 (2007).
49. Rakha, E. A. et al. Prognostic markers in triple-negative breast cancer. Cancer 109, 25–32 (2007).
50. Dent, R. et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin. Cancer Res. 13, 4429–4434 (2007).
51. Kulbe, H. et al. The inflammatory cytokine tumor necrosis factor-alpha regulates chemokine receptor expression on ovarian cancer cells. Cancer Res. 65, 10355–10362 (2005).
52. Hamaguchi, T. et al. TNF inhibitor suppresses bone metastasis in a breast cancer cell line. Biochem. Biophys. Res. Commun. 407, 525–530 (2011).
53. Malin, D. et al. Enhanced metastasis suppression by targeting TRAIL receptor 2 in a murine model of triple-negative breast cancer. Clin. Cancer Res. 17, 5005–5015 (2011).
54. Yan, D. et al. Expression of TNF-alpha leader sequence renders MCF-7 tumor cells resistant to the cytotoxicity of soluble TNF-alpha. Breast Cancer Res. Treat 116, 91–102 (2009).
55. Zhang, H. et al. Transmembrane TNF-alpha mediates "forward" and "reverse" signaling, inducing cell death or survival via the NF-kappaB pathway in Raji Burkitt lymphoma cells. J. Leukoc Biol. 84, 789–797 (2008).
56. Zhai, K., Ding, J. & Zhou, Y. Different role of tumor necrosis factor-alpha polymorphism in non-Hodgkin lymphomas among Caucasian and Asian populations: a meta-analysis. Int. J. Mol. Sci. 15, 7684–7698 (2014).